ArticlebioRxiv : the preprint server for biology2025
Gene-based calibration of high-throughput functional assays for clinical variant classification.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
High-throughput functional assays measure the effects of variants on macromolecular function and can aid in reclassifying the rapidly growing number of variants of uncertain significance. Under the current clinical variant classification guidelines, using functional data as a line of evidence to assert pathogenicity relies on determining assay score thresholds that define variants as functionally normal or functionally abnormal. These thresholds are designed to maximize the separation of variants with known clinical effects (benign, pathogenic) and often incorporate expert opinion. However, this approach lacks the rigor of calibration, in which a variant's posterior probability of pathogenicity must be estimated from the raw experimental score and mapped to discrete evidence strengths. To build upon the existing guidelines, we introduce and evaluate a method for calibrating continuous high-throughput functional data as a line of evidence in clinical variant classification. Assay score distributions of synonymous variants and variants appearing in gnomAD for a given functional scoreset are jointly modeled with score distributions of known pathogenic and benign variants using a multi-sample skew normal mixture of distributions. This model is learned using a constrained expectation-maximization algorithm that provably preserves the monotonicity of pathogenicity posteriors and is subsequently used to calculate variant-specific evidence strengths for use in the clinic. Using 24 datasets from 14 genes, we first assess the model's ability to capture assay score distributions. We then demonstrate its potential impact on reclassifying variants by comparing the evidence strengths assigned at the variant-level with those assigned uniformly to all functionally normal and abnormal variants under the existing ClinGen guidelines. An improved classification of variants will directly improve the accuracy of genetic diagnosis and subsequent medical management for individuals affected by Mendelian disorders. Availability: https://github.com/dzeiberg/mave_calibration.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.